Chengjun Jiang
YOU?
Author Swipe
View article: A First‐In‐Human Phase 1 Study of a Novel <scp>BCMA</scp> × <scp>CD3</scp> Bispecific T Cell Engager <scp>EMB</scp> ‐06 in Relapsed or Refractory Multiple Myeloma
A First‐In‐Human Phase 1 Study of a Novel <span>BCMA</span> × <span>CD3</span> Bispecific T Cell Engager <span>EMB</span> ‐06 in Relapsed or Refractory Multiple Myeloma Open
View article: The crystal structure of 4-(3-carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-ium 2-fluorobenzoate hydrate, C <sub>23</sub> H <sub>25</sub> F <sub>2</sub> N <sub>3</sub> O <sub>6</sub>
The crystal structure of 4-(3-carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-ium 2-fluorobenzoate hydrate, C <sub>23</sub> H <sub>25</sub> F <sub>2</sub> N <sub>3</sub> O <sub>6</sub> Open
C 23 H 25 F 2 N 3 O 6 , triclinic, P 1 ‾ $\overline{1}$ , a = 7.3162(3) Å, b = 10.4107(5) Å, c = 15.4537(7) Å, α = 84.3830(10)°, β = 82.7090(10)°, γ = 70.1110(10)°, V = 1096.01(9) Å 3 , Z = 2, R gt ( F ) = 0.0376, wR ref ( F 2 ) = 0.…
View article: Step-down RH improves plums drying behavior, quality attributes, and 3E (energy, environmental, economic) equipment performance by changing its ultrastructure and water distribution
Step-down RH improves plums drying behavior, quality attributes, and 3E (energy, environmental, economic) equipment performance by changing its ultrastructure and water distribution Open
View article: First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors
First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors Open
View article: The crystal structure of 4-(3-carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-ium 4-hydroxy-3,5-dimethoxybenzoate monohydrate, C<sub>25</sub>H<sub>30</sub>FN<sub>3</sub>O<sub>9</sub>
The crystal structure of 4-(3-carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-ium 4-hydroxy-3,5-dimethoxybenzoate monohydrate, C<sub>25</sub>H<sub>30</sub>FN<sub>3</sub>O<sub>9</sub> Open
C 25 H 30 FN 3 O 9 , monoclinic, P 2 1 / n , a = 16.3585(4) Å, b = 7.8763(2) Å, c = 18.7735(4) Å, ꞵ = 90.5690(10)°, V = 2418.74(10) Å 3 , Z = 4, R gt ( F ) = 0.0410, wR ref ( F 2 ) = 0.1055, T = 170 K.
View article: Using Pharmacokinetic and Pharmacodynamic Analysis to Optimize the Dosing Regimens of Fanastomig (<scp>EMB</scp>‐02) in Patients With Advanced Solid Tumors
Using Pharmacokinetic and Pharmacodynamic Analysis to Optimize the Dosing Regimens of Fanastomig (<span>EMB</span>‐02) in Patients With Advanced Solid Tumors Open
Fanastomig (also known as EMB‐02) is a bispecific antibody targeting programmed cell death protein‐1(PD‐1) and lymphocyte activation gene‐3 (LAG‐3), developed for the treatment of advanced solid tumors. A first‐in‐human (FIH) Phase I study…
View article: The crystal structure of 1-phenylethan-1-aminium 4-hydroxy-3,5-dimethoxybenzoate C<sub>17</sub>H<sub>21</sub>NO<sub>5</sub>
The crystal structure of 1-phenylethan-1-aminium 4-hydroxy-3,5-dimethoxybenzoate C<sub>17</sub>H<sub>21</sub>NO<sub>5</sub> Open
C 17 H 21 NO 5 , monoclinic, P 2 1 (no. 4), a = 6.0322(2) Å, b = 16.0271(6) Å, c = 9.0421(3) Å, β = 105.568(2)°, V = 842.11(5) Å 3 , Z = 2, R gt ( F ) = 0.0384, wR ref ( F 2 ) = 0.1008, T = 170 K.
View article: Effect of Surfactants on the Solubility of Atorvastatin Calcium
Effect of Surfactants on the Solubility of Atorvastatin Calcium Open
View article: The structure of <i>t</i>-butyl 7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1<i>H</i>-pyrrol-1-yl]-3,5-dihydroxyheptanoate, C<sub>37</sub>H<sub>43</sub>FN<sub>2</sub>O<sub>5</sub>
The structure of <i>t</i>-butyl 7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1<i>H</i>-pyrrol-1-yl]-3,5-dihydroxyheptanoate, C<sub>37</sub>H<sub>43</sub>FN<sub>2</sub>O<sub>5</sub> Open
C 37 H 43 FN 2 O 5 , monoclinic, P 2 1 (no. 4), a = 13.8818(6) Å, b = 8.7373(4) Å, c = 15.6295(7) Å, β = 113.356(2)°, V = 1740.36(14) Å 3 , Z = 2, R gt ( F ) = 0.0527, wR ref ( F 2 ) = 0.1346, T = 170 K.
View article: Influence of network latency and bandwidth on robot-assisted laparoscopic telesurgery: A pre-clinical experiment
Influence of network latency and bandwidth on robot-assisted laparoscopic telesurgery: A pre-clinical experiment Open
Background: Telesurgery has the potential to overcome spatial limitations for surgeons, which depends on surgical robot and the quality of network communication. However, the influence of network latency and bandwidth on telesurgery is not…
View article: The crystal structure of 4-(3-carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-ium 2-carboxy-6-nitrobenzoate monohydrate, C<sub>24</sub>H<sub>25</sub>FN<sub>4</sub>O<sub>10</sub>
The crystal structure of 4-(3-carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-ium 2-carboxy-6-nitrobenzoate monohydrate, C<sub>24</sub>H<sub>25</sub>FN<sub>4</sub>O<sub>10</sub> Open
C 24 H 25 FN 4 O 10 , triclinic, P 1̄ (no. 2), a = 7.7217(3) Å, b = 9.9451(4) Å, c = 15.9291(6) Å, α = 101.741(1) ∘ , β = 98.762(1) ∘ , γ = 96.148(1) ∘ , V = 1171.56(8) Å 3 , Z = 2, R gt ( F ) = 0.0389, wR ref ( F 2 ) = 0.1162, T = 170 K.
View article: Study of The Resolution of English Relative Clause Attachment Ambiguities by Trilingual Learners
Study of The Resolution of English Relative Clause Attachment Ambiguities by Trilingual Learners Open
The study of the relative clause (RC) attachment is important in revealing the internal psychological processes of processing ambiguous sentences. It is worth exploring whether the existing attachment hypotheses apply to second and third-l…
View article: The crystal structure of t-butyl 7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1<i>H</i>-indol-2-yl]-3,5-dihydroxyhept-6-enoate, C<sub>28</sub>H<sub>34</sub>FNO<sub>4</sub>
The crystal structure of t-butyl 7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1<i>H</i>-indol-2-yl]-3,5-dihydroxyhept-6-enoate, C<sub>28</sub>H<sub>34</sub>FNO<sub>4</sub> Open
C 28 H 34 FNO 4 , monoclinic, C 2/ c (no. 15), a = 21.7795(12) Å, b = 5.9103(4) Å, c = 39.830(2) Å, β = 100.866(3)°, V = 5035.1(5) Å 3 , Z = 8, R gt ( F ) = 0.0487, w R ref ( F 2 ) = 0.1376, T = 170 K.
View article: The crystal structure of <i>t</i>-butyl 7-[4-(4-fluorophenyl)-2-[(methanesulfonyl)(methyl)amino]-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate, C<sub>26</sub>H<sub>36</sub>FN<sub>3</sub>O<sub>6</sub>S
The crystal structure of <i>t</i>-butyl 7-[4-(4-fluorophenyl)-2-[(methanesulfonyl)(methyl)amino]-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate, C<sub>26</sub>H<sub>36</sub>FN<sub>3</sub>O<sub>6</sub>S Open
C 26 H 36 FN 3 O 6 S, monoclinic, P 2 1 (no. 4), a = 10.6615(4) Å, b = 8.7470(3) Å, c = 29.4342(11) Å, α = 9°, β = 95.6130(10)°, γ = 90°, V = 2731.76(17) Å 3 , Z = 4, R gt ${R}_{\text{gt}}$ ( F ) = 0.0439, w R ref $\mathrm{w}{R…
View article: 1528 A phase I study of a novel BCMA×CD3 bispecific antibody EMB06 in relapsed or refractory multiple myeloma
1528 A phase I study of a novel BCMA×CD3 bispecific antibody EMB06 in relapsed or refractory multiple myeloma Open
Background Despite recent advances in T-cell engager based multiple myeloma therapies, high rate of cytokine release syndrome (CRS) and severe neurotoxicity remains a challenge in clinic. EMB-06 is a novel 2+2 BCMA×CD3 T-Cell engaging bisp…
View article: The crystal structure of 3-nitrobenzene-1,2-dicarboxylic acid–2-ethoxybenzamide (1/1), C<sub>17</sub>H<sub>16</sub>N<sub>2</sub>O<sub>8</sub>
The crystal structure of 3-nitrobenzene-1,2-dicarboxylic acid–2-ethoxybenzamide (1/1), C<sub>17</sub>H<sub>16</sub>N<sub>2</sub>O<sub>8</sub> Open
C 17 H 16 N 2 O 8 , monoclinic, P 2 1 / c (no. 14), a = 7.0825(4) Å, b = 15.6168(9) Å, c = 15.1086(9) Å, β = 93.3830(10)°, V = 1668.19(17) Å 3 , Z = 4, R gt ( F ) = 0.0543, wR ref ( F 2 ) = 0.1443, T = 170.15 K.
View article: The crystal structure of 4-(3-carboxy-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4- dihydroquinolin-7-yl)-2-methylpiperazin-1-ium 2,5-dihydroxybenzoate methanol solvate, C<sub>27</sub>H<sub>32</sub>FN<sub>3</sub>O<sub>9</sub>
The crystal structure of 4-(3-carboxy-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4- dihydroquinolin-7-yl)-2-methylpiperazin-1-ium 2,5-dihydroxybenzoate methanol solvate, C<sub>27</sub>H<sub>32</sub>FN<sub>3</sub>O<sub>9</sub> Open
C 27 H 32 FN 3 O 9 , triclinic, P 1 ‾ $P\overline{1}$ (no. 2), a = 8.0932(4) Å, b = 11.8392(7) Å, c = 14.6782(8) Å, α = 87.860(3) ∘ , β = 76.795(2) ∘ , γ = 78.317(2)°, V = 1340.81(13) Å 3 , Z = 2, R gt ( F ) = 0.0559, wR ref ( F 2 ) …
View article: The crystal structure of 3,4-dihydroxybenzoic acid – 3-[7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3<i>H</i>-[1,2,3] triazolo[4,5-<i>d</i>]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol – water (1/1/1), C<sub>30</sub>H<sub>36</sub>F<sub>2</sub>N<sub>6</sub>O<sub>9</sub>S
The crystal structure of 3,4-dihydroxybenzoic acid – 3-[7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3<i>H</i>-[1,2,3] triazolo[4,5-<i>d</i>]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol – water (1/1/1), C<sub>30</sub>H<sub>36</sub>F<sub>2</sub>N<sub>6</sub>O<sub>9</sub>S Open
C 30 H 36 F 2 N 6 O 9 S, orthorhombic, P 2 1 2 1 2 1 (no. 19), a = 5.2364(8) Å, b = 10.0250(14) Å, c = 59.689(9) Å, V = 3133.4(8) Å 3 , Z = 4, R gt ( F ) = 0.0384, wR ref ( F 2 ) = 0.0969, T = 170 K.
View article: New ethenzamide-trimesic acid cocrystal: Equilibrium solubility
New ethenzamide-trimesic acid cocrystal: Equilibrium solubility Open
To study the influence of drug cocrystal on the solubility of active pharmaceutical ingredients (APIs). The ETZ·2TMA·MeOH cocrystal was obtained by the solution evaporation crystallization method. The cocrystal structure was characterized …
View article: New Ethenzamide-Trimesic Acid Cocrystal: Equilibrium Solubility
New Ethenzamide-Trimesic Acid Cocrystal: Equilibrium Solubility Open
Ethenzamide, a non-steroidal anti-inflammatory drug, is used to treat pain, inflammation, fever and rheumatism.However, it has low solubility and belongs to class II of the biopharmaceutical classification system.In order to improve the so…
View article: The crystal structure of 3-hydroxy-5-oxo-4-propanoylcyclohex-3-ene-1-carboxylic monohydrate, C<sub>10</sub>H<sub>14</sub>O<sub>6</sub>
The crystal structure of 3-hydroxy-5-oxo-4-propanoylcyclohex-3-ene-1-carboxylic monohydrate, C<sub>10</sub>H<sub>14</sub>O<sub>6</sub> Open
C 10 H 14 O 6 , triclinic, P 1 ‾ $P\overline{1}$ (no. 2), a = 7.5531(2) Å, b = 9.3964(3) Å, c = 9.5089(3) Å, α = 61.8330(10)°, β = 68.6230(10)°, γ = 86.5750(10)°, V = 548.80(3) Å 3 , Z = 2, R gt ( F ) = 0.0485, wR ref ( F 2 ) = 0.143…
View article: The crystal structure of oxalic acid – 2-ethoxybenzamide (2/1), C<sub>20</sub>H<sub>24</sub>N<sub>2</sub>O<sub>8</sub>
The crystal structure of oxalic acid – 2-ethoxybenzamide (2/1), C<sub>20</sub>H<sub>24</sub>N<sub>2</sub>O<sub>8</sub> Open
C 20 H 24 N 2 O 8 , monoclinic, P 2 1 / n (no. 14), a = 3.8981(3) Å, b = 16.0675(11) Å, c = 16.2908(10) Å, β = 94.537(3)°, V = 1017.14(12) Å 3 , Z = 2, R gt ( F ) = 0.0634, wR ref ( F 2 ) = 0.1746, T = 170 K.
View article: The crystal structure of 2,3,4-trihydroxybenzoic- acid—pyrazine-2-carboxamide—water (1/1/1), C<sub>12</sub>H<sub>13</sub>N<sub>3</sub>O<sub>7</sub>
The crystal structure of 2,3,4-trihydroxybenzoic- acid—pyrazine-2-carboxamide—water (1/1/1), C<sub>12</sub>H<sub>13</sub>N<sub>3</sub>O<sub>7</sub> Open
C 12 H 13 N 3 O 7 , triclinic, P 1 ‾ $P\overline{1}$ (no. 2), a = 6.9878(9) Å, b = 7.0956(8) Å, c = 13.8113(15) Å, α = 88.745(5)°, β = 87.764(5)°, γ = 75.785(5)°, V = 663.27(14) Å 3 , Z = 2, R gt ( F ) = 0.0455, wR ref ( F 2 ) = 0.12…
View article: The crystal structure of 3-nitrobenzene-1,2-dicarboxylic acid—pyrazine-2-carboxamide(1/1), C<sub>13</sub>H<sub>10</sub>N<sub>4</sub>O<sub>7</sub>
The crystal structure of 3-nitrobenzene-1,2-dicarboxylic acid—pyrazine-2-carboxamide(1/1), C<sub>13</sub>H<sub>10</sub>N<sub>4</sub>O<sub>7</sub> Open
C 13 H 10 N 4 O 7 , monoclinic, P 2 1 / n (no. 14), a = 10.7017(7) Å, b = 7.1240(5) Å, c = 19.0878(13) Å, β = 99.280(3)°, V = 1436.19(17) Å 3 , Z = 4, R gt ( F ) = 0.0586, wR ref ( F 2 ) = 0.1746, T = 296.15 K.
View article: CCDC 2183838: Experimental Crystal Structure Determination
CCDC 2183838: Experimental Crystal Structure Determination Open
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available …
View article: The crystal structure of 4,4′-bipyridine-5,6,7-trihydroxy-2-phenyl-4<i>H</i>-chromen-4-one-water(1/2/2), C<sub>40</sub>H<sub>32</sub>N<sub>2</sub>O<sub>12</sub>
The crystal structure of 4,4′-bipyridine-5,6,7-trihydroxy-2-phenyl-4<i>H</i>-chromen-4-one-water(1/2/2), C<sub>40</sub>H<sub>32</sub>N<sub>2</sub>O<sub>12</sub> Open
C 40 H 32 N 2 O 12 , triclinic, P 1 ‾ $P\overline{1}$ (no. 2), a = 7.403(3) Å, b = 8.275(3) Å, c = 14.571(4) Å, α = 106.115(15)°, β = 98.239(16)°, γ = 95.054(19)°, V = 840.9(5) Å 3 , Z = 1, R gt ( F ) = 0.0353, w R ref ( F 2 ) = 0.09…
View article: The crystal structure of the cocrystal 4-hydroxy-3,5-dimethoxybenzoic acid–pyrazine-2-carboxamide(1/1), C<sub>14</sub>H<sub>15</sub>N<sub>3</sub>O<sub>6</sub>
The crystal structure of the cocrystal 4-hydroxy-3,5-dimethoxybenzoic acid–pyrazine-2-carboxamide(1/1), C<sub>14</sub>H<sub>15</sub>N<sub>3</sub>O<sub>6</sub> Open
C 14 H 15 N 3 O 6 , monoclinic, C 2/ c (no. 15), a = 30.1620(13) Å, b = 3.8559(2) Å, c = 27.3897(13) Å, β = 117.610(4)°, V = 2822.7(3) Å 3 , Z = 8, R gt ( F ) = 0.0332, wR ref ( F 2 ) = 0.0904, T = 170 K.
View article: The crystal structure of bis(4-(6-carboxy-8-ethyl-3-fluoro-5-oxo-5,8-dihydro-1,8-naphthyridin-2- yl)piperazin-1-ium) adipate tetrahydrate, C<sub>36</sub>H<sub>52</sub>F<sub>2</sub>N<sub>8</sub>O<sub>14</sub>
The crystal structure of bis(4-(6-carboxy-8-ethyl-3-fluoro-5-oxo-5,8-dihydro-1,8-naphthyridin-2- yl)piperazin-1-ium) adipate tetrahydrate, C<sub>36</sub>H<sub>52</sub>F<sub>2</sub>N<sub>8</sub>O<sub>14</sub> Open
C 36 H 52 F 2 N 8 O 14 , triclinic, P 1 ‾ $\overline{1}$ (no. 2), a = 6.9775(4) Å, b = 9.0785(6) Å, c = 16.8942(10) Å, β = 92.778(2)°, V = 990.91(11) Å 3 , Z = 1, R gt ( F ) = 0.0397, wR ref ( F 2 ) = 0.1088, T = 170 K.
View article: Preparation and <i>in Vitro</i> Evaluation of Osmotic-Pump Lorcaserin-hydrochloride Controlled-Release Tablets
Preparation and <i>in Vitro</i> Evaluation of Osmotic-Pump Lorcaserin-hydrochloride Controlled-Release Tablets Open
Long-term and constant-release osmotic-pump lorcaserin hydrochloride controlled-release tablets (OP LH CRTs) were prepared, to investigate the influencing factors of LH release and optimize the formulation. The mechanism of release of LH f…
View article: Reaction Kinetics Study of Catalytical Hydrogenation of Furfural in Liquid Phase
Reaction Kinetics Study of Catalytical Hydrogenation of Furfural in Liquid Phase Open
Hydrogenation of furfural in the presence of Raney nickel catalyst is employed for the preparation of tetrahydrofurfuryl alcohol.The effects of stirring rate, reaction time and reaction temperature on the yield of tetrahydrofurfuryl alcoho…